Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-993X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics ; volume:22 ; number:1 ; day:10 ; month:5 ; year:2021 ; pages:1-13 ; date:12.2021
Respiratory research ; 22, Heft 1 (10.5.2021), 1-13, 12.2021

Urheber
Liu, Mark C.
Chipps, Bradley
Munoz, Xavier
Devouassoux, Gilles
Bergna, Miguel
Smith, Steven G.
Price, Robert G.
Galkin, Dmitry V.
Azmi, Jay
Mouneimne, Dalal
Albers, Frank C.
Chapman, Kenneth R.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12931-021-01733-9
URN
urn:nbn:de:101:1-2021091121433113533916
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 05:26 UTC

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Liu, Mark C.
  • Chipps, Bradley
  • Munoz, Xavier
  • Devouassoux, Gilles
  • Bergna, Miguel
  • Smith, Steven G.
  • Price, Robert G.
  • Galkin, Dmitry V.
  • Azmi, Jay
  • Mouneimne, Dalal
  • Albers, Frank C.
  • Chapman, Kenneth R.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

Severe asthma and the omalizumab option

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Eosinophilic bioactivities in severe asthma

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Verbundene Objekte